Effectiveness of Bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting

被引：86

作者：

Koster, A ^{[1
]}

Spiess, B

Chew, DP

Krabatsch, T

Tambeur, L

DeAnda, A

Hetzer, R

Kuppe, H

Smedira, NG

Lincoff, AM

机构：

[1] Deutsch Herzzentrum, Dept Anesthesia, Berlin, Germany

[2] Deutsch Herzzentrum, Dept Cardiothorac & Vasc Surg, Berlin, Germany

[3] Virginia Commonwealth Univ, Dept Cardiothorac Anesthesia, Richmond, VA USA

[4] Virginia Commonwealth Univ, Dept Cardiothorac Surg, Richmond, VA USA

[5] Flinders Med Ctr, Dept Cardiol, Bedford Pk, SA, Australia

[6] Cleveland Clin Fdn, Dept Cardiothorac Surg, Cleveland, OH 44195 USA

[7] Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2004年 / 93卷 / 03期

关键词：

D O I：

10.1016/j.amjcard.2003.10.021

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We investigated the use of bivalirudin as an anticoagulant therapy during cardiopulmonary bypass in 20 patients who underwent coronary artery bypass grafting. Primary end points consisted of clinical outcome data, whereas secondary end points focused on blood loss, transfusions, pharmacokinetics, and monitoring. Our data provide the first evidence of clinical feasibility of anticoagulation with bivalirudin during cardiopulmonary bypass. (C) 2004 by Excerpta Medica, Inc.

引用

页码：356 / 359

页数：4

共 5 条

[1]

BATES SM, 2000, J INVASIVE CARDIOL, V12, pF1

[2] An assessment of different filter systems for extracorporeal elimination of bivalirudin:: An in vitro study [J].

Koster, A ;

Chew, D ;

Gründel, M ;

Hausmann, H ;

Grauhan, O ;

Kuppe, H ;

Spiess, BD .

ANESTHESIA AND ANALGESIA, 2003, 96 (05) :1316-1319

[3] Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass [J].

Koster, A ;

Chew, D ;

Gründel, M ;

Bauer, M ;

Kuppe, H ;

Spiess, BD .

ANESTHESIA AND ANALGESIA, 2003, 96 (02) :383-386

[4] Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention - REPLACE-2 Randomized Trial [J].

Lincoff, AM ;

Bittl, JA ;

Harrington, RA ;

Feit, F ;

Kleiman, NS ;

Jackman, JD ;

Sarembock, IJ ;

Cohen, DJ ;

Spriggs, D ;

Ebrahimi, R ;

Keren, G ;

Carr, J ;

Cohen, EA ;

Betriu, A ;

Desmet, W ;

Kereiakes, DJ ;

Rutsch, W ;

Wilcox, RG ;

de Feyter, PJ ;

Vahanian, A ;

Topol, EJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (07) :853-863

[5] Aspirin and mortality from coronary bypass surgery [J].

Mangano, DT ;

Saidman, L ;

Levin, J ;

Barash, P ;

Dietzel, C ;

Herskowitz, A ;

Ley, C ;

Hsu, P ;

Kardatzke, D ;

Wang, S ;

Tudor, IC ;

Beatty, D ;

Xavier, B ;

Kerkela, S ;

Aronson, S ;

Comunale, M ;

D'Ambra, M ;

Eaton, M ;

Engelman, R ;

Fitch, J ;

Grichnik, K ;

Hantler, CB ;

Hillel, Z ;

Kanchuger, M ;

Ostrowski, J ;

Mangano, CM ;

Mathew, J ;

Fontes, M ;

Barash, P ;

McSweeney, M ;

Wolman, R ;

Napolitano, CA ;

Nesbitt, LA ;

Nijhawan, N ;

Nussmeier, N ;

Pivalizza, EG ;

Polson, S ;

Ramsay, J ;

Roach, G ;

Schwann, N ;

Shenaq, S ;

Shevde, K ;

Shore-Lesserson, L ;

Bronheim, D ;

Wahr, J ;

Spiess, B ;

Wallace, A ;

Metzler, H ;

Ansley, D ;

O'Connor, JP .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (17) :1309-1317

← 1 →